Indications › Alcohol use disorder
GLP‑1 drugs in alcohol use disorder
Which incretin agents are being studied in alcohol use disorder, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 16
- Active
- 9
- Results scheduled
- 2
- Molecules studied
- 5
- Sponsors
- 15
No GLP‑1 or incretin drug is FDA-approved for alcohol use disorder. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for alcohol use disorder, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 1 of the 16 trials on file is phase 3 or later — the stage sized for a regulator to act on, against 15 still in early phases. 15 distinct sponsors are involved, 2 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
exenatide · mazdutide · pemvidutide · semaglutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2027-07-30 | tirzepatide | Tirzepatide in MetALD NCT07046819 · National Institute on Alcohol Abuse and Alcoholism (NIAAA) | P2 | 120 |
| 2028-08-01 | tirzepatide | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder NCT06939088 · Anders Fink-Jensen, MD, DMSci | P2 | 108 |
Trials on file
All 16 incretin trials recorded in this indication, active first.